Intrinsic clotting factors in dependency of age, sex, body mass index, and oral contraceptives: Definition and risk of elevated clotting factor levels

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 7, 2009, Pages 524-534

  Luxembourg, Beate ^a   Schmitt, Joern ^b   Humpich, Marek ^a   Glowatzki, Matthias ^c   Seifried, Erhard ^d   Lindhoff Last, Edelgard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Division of Cardiology

^c SPSS GmbH Software   (Germany)

^d Blood Transfusion Center of the German Red Cross   (Germany)

Author keywords

Coagulation factor; Factor IX; Factor VIII; Factor XI; Factor XII

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; ORAL CONTRACEPTIVE AGENT; BLOOD CLOTTING FACTOR;

ADULT; AGE; AGED; ARTICLE; BLOOD CLOTTING; BLOOD DONOR; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; VENOUS THROMBOEMBOLISM; ADOLESCENT; BLOOD; MIDDLE AGED; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BLOOD COAGULATION FACTORS; BODY MASS INDEX; CONTRACEPTIVES, ORAL; FACTOR IX; FACTOR VIII; FACTOR XI; FACTOR XII; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SEX FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 70349841105     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832d9b58     Document Type: Article

References (46)

1. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345:152-155.
2. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77:825-828.
3. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83:5-9.
4. Bloemenkamp KW, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999; 82:1024-1027.
5. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reaction. Thromb Haemost 1999; 81:680-683.
6. Wells PS, Langlois NJ, Webster MA, Jaffey J, Anderson JA. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada: is it necessary to define a new upper reference range for VIII? Thromb Haemost 2005; 93:842-846.
7. Tirado I, Mateo J, Soria JM, Oliver A, Martínez-Sánchez E, Vallvé C, et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005; 93:468-474.
8. Erkekol FO, Ulu A, Numanoglu N, Akar N. High plasma levels of factor VIII: an important risk factor for isolated pulmonary embolism. Respirology 2006; 11:70-74.
9. Kyrle PA, Minar E, HirschlM, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457-462.
10. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342:696-701.
11. Van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95:3678-3682.
12. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationship to hormone replacement therapy. Thromb Haemost 2000; 83:530-535.
13. Weltermann A, Eichinger S,BialonczykC, Minar E, Hirschl M, Quehenberger P, et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 2003; 1:28-32.
14. Koster T, Rosendaal FR, Briët E, Vandenbroucke JP. John Hageman's factor and deep-vein thrombosis: Leiden Thrombophilia study. Br J Haematol 1994; 87:422-424.
15. Von Kä nel R, Wuillemin WA, Furlan M, Lämmle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 1992; 3:555-561.
16. Mannhalter C, Fischer M, Hopmeier P, Deutsch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1:259-263.
17. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992; 68:285-290.
18. Gallimore MJ, Harris SL, Jones DW, Winter M. Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis. Thromb Res 2004; 144:91-96.
19. Schambeck CM, Hinney K, Haubitz I, Mansouri Taleghani B, Wahler D, Keller F. Familial clustering of high factor VIII levels in patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 2001; 21:289-292.
20. Soria JM, Almasy L, Souto JC, Buil A, Martinez-Sanchez E, Mateo J, et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003; 101:163-167.
21. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, VIII and fibrinogen in an industrial population. I: baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54:475-479. (Pubitemid 16255676)
22. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers. The third Glasgow MONICA survey I: Illustrative reference ranges by age, sex, and hormone use. Br J Haematol 1997; 97:775-784. (Pubitemid 27321375)
23. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70:380-385.
24. Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle factors and coagulation activation markers: the Caerphilly Study. Blood Coagul Fibrinolysis 2001; 12:721-728.
25. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16:368-374. (Pubitemid 26084311)
26. Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators. Am J Epidemiol 1996; 143:665-676.
27. Gevers Leuven JA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109:631-636.
28. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84:4-8. (Pubitemid 30433659)
29. Favaloro EJ. Is elevated factor VIII a risk factor for venous thromboembolism in Canada? Thromb Haemost 2005; 94:1112-1113.
30. Patel RK, Ford E, Thumpston J, Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost 2003; 90:835-838.
31. Sweeney JD, Hoernig LA. Age-dependent effect on the level of factor IX. Am J Clin Pathol 1993; 99:687-688.
32. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78:315-326.
33. Briet E, van Tilburg NH, Veltkamp JJ. Oral contraception and the detection of carriers in haemophilia B. Thromb Res 1978; 13:379-388.
34. Kurachi S, Deyashiki Y, Takeshita J, Kurachi K. Genetic mechanisms of age regulation of human blood coagulation factor IX. Science 1999; 285:739-743.
35. Kurachi K, Kurachi S. Genetic mechanisms of age regulation of blood coagulation: factor IX model. Arterioscler Thromb Vasc Biol 2000; 20:902-906. (Pubitemid 30207561)
36. Berliner JI, Rybicki AC, Kaplan RC, Monrad ES, Freeman R, Billett HH. Elevated levels of factor XI are associated with cardiovascular disease in women. Thromb Res 2002; 107:55-60.
37. Tanis B, Algra A, van der Graaf Y, Helmerhorst F, Rosendaal F. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol 2006; 77:67-73.
38. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007; 104:6388-6393.
39. Renné T, Nieswandt B, Gailani D. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis 2006; 36:148-151.
40. Fossum S, Hoem NO, Johannesen S, Korpberget M, Nylund E, Sandem S, et al. Contact factors in plasma from women on oral contraception: significance of factor XI for the measured activity of factor XII. Thromb Res 1994; 74:477-485.
41. Notelovitz M, Kitchens CS, Khan FY. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial. Am J Obstet Gynecol 1992; 167:1255-1261.
42. Cohen H,Mackie IJ, Walshe K, Gillmer MD,Machin SJ. A comparison of the effects of two triphasic oral contraceptives on haemostasis. Br J Haematol 1988; 69:259-263.
43. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost 1998; 80:382-387.
44. Gordon EM, Douglas JG, Ratnoff OD, Arafah BM. The influence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomized rat. Blood 1985; 66:602-605.
45. Citarella F, Misiti S, Felici A, Farsetti A, Pontecorvi A, Fantoni A. Estrogen induction and contact phase activation of human factor XII. Steroids 1996; 61:270-276.
46. Tirado I, Soria JM, Mateo J, Oliver A, Souto JC, Santamaria A, et al. Association after linkage analysis indicates that homozygosity for the 46CT polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 2004; 91:899-904.